INmune Bio, Inc.
INMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $93,138 | $202,466 | $113,657 | $164,536 |
| - Cash | $20,922 | $35,848 | $52,153 | $74,810 |
| + Debt | $384 | $10,437 | $15,310 | $15,234 |
| Enterprise Value | $72,600 | $177,055 | $76,814 | $104,960 |
| Revenue | $14 | $155 | $374 | $181 |
| % Growth | -91% | -58.6% | 106.6% | – |
| Gross Profit | $14 | $155 | $374 | $181 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$42,082 | $0 | $0 | $0 |
| % Margin | -300,585.7% | 0% | 0% | 0% |
| Net Income | -$42,082 | -$30,008 | -$27,299 | -$30,340 |
| % Margin | -300,585.7% | -19,360% | -7,299.2% | -16,762.4% |
| EPS Diluted | -2.11 | -1.67 | -1.52 | -1.88 |
| % Growth | -26.3% | -9.9% | 19.1% | – |
| Operating Cash Flow | -$33,361 | -$11,980 | -$22,686 | -$28,504 |
| Capital Expenditures | $0 | $0 | $0 | -$15,000 |
| Free Cash Flow | -$33,361 | -$11,980 | -$22,686 | -$43,504 |